Optimising inhaled polymyxins as a vital therapy for pulmonary infections: A novel biochemical, molecular imaging and systems pharmacology approach

优化吸入多粘菌素作为肺部感染的重要治疗方法：一种新颖的生化、分子成像和系统药理学方法

• 批准号: nhmrc : GNT1104581
• 负责人: A/Pr Tony Velkov
• 金额: $ 72.8万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/optimising-inhaled-polymyxins-pharmacology-approach/1346372
• 关键词: Optimising; inhaled; polymyxins; vital; therapy

Lung infection is a leading cause of death in Australia and globally. Many bacterial pathogens are resistant to almost all current antibiotics. A class of ‘old’ antibiotics, polymyxins, are the last option for bacterial ‘superbugs’. Unfortunately, the current use of polymyxins is suboptimal and can cause severe kidney toxicity. This multi-disciplinary project will apply cutting-edge techniques to optimise inhaled polymyxin therapy for treatment of life-threatening pulmonary infections.

肺部感染是澳大利亚和全球的主要死亡原因。许多细菌病原体对几乎所有现有的抗生素都有耐药性。一类“古老”的抗生素，多粘菌素，是细菌“超级细菌”的最后选择。不幸的是，目前使用的多粘菌素是次优的，并可能导致严重的肾毒性。这个多学科项目将应用尖端技术来优化吸入多粘菌素治疗危及生命的肺部感染。